Researchers have developed a new tool to help clinicians tailor personalized treatment plans for patients with a rare blood cancer called chronic myelomonocytic leukemia (CMML). The tool, called the international CMML Prognostic Scoring System (iCPSS), may help improve a patient’s chance of survival.
This article was originally published on MedicalXpress.com

